Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rejuveinix in COVID-19
NCT04708340Phase 2Unknown
- Sponsor
- Reven Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Oct 2022
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
A Phase 2 trial of rejuveinix in coronavirus disease 2019 (COVID-19), sponsored by Reven Pharmaceuticals. Status: unknown.
02
Drugs
rejuveinix
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04708340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04708340.